Herborium® Reports 20% Increase in Gross Profit for First Quarter of 2017
18 4월 2017 - 11:18PM
InvestorsHub NewsWire
Fort Lee, N.J.
-- April 18, 2017 -- InvestorsHub NewsWire --
Herborium®
Group, Inc. (OTC Pink:
HBRM), www.Herborium.com,
a Botanical Therapeutics®
Company and the provider of unique all botanical medicinal products
(Botanical Therapeutics®) that target dermatological issues such as
acne, and other health and wellness concerns, announced today
that its First Quarter of 2017 is marked by two-digit growth
of the Company’s Revenues and Gross Profit in comparison to the
same period of 2016. .
The
Achievements of the Q1, 2017:
- -Herborium’s revenue increased 18%
in comparison to Q1, 2016, to
approximately $223,000 in sales.
-The Company's gross
profit increased 20%, over Q1, 2016, to $135,500 in
2017.
-Operating income loss
was decreased 80% in comparison to operating income
loss in Q1, 2016
-The Gross margin
remained unchanged at the healthy 65%
-AcnEase US Facebook
exceeded 75,000 likes and AcnEase France Facebook exceeded 55,000
likes
-In the First Quarter
of 2017 the company built the high quality Spanish Website and
Social Media platform for AcnEase to prepare monetization of
the $1.4 trillion US Hispanic
Market opportunity
The above milestones are an
integral part of the Company’s growth strategy and its efforts to
increase shareholders value. In addition to the above, the First
Quarter of 2017 also brought the following important brand and
sales building accomplishments:
- -The Company
established relationship with a number of top new influencers in
USA, France, Canada, Spain and -Argentina to increase global brand
visibility.
-The Company initiated
number of efforts to increase wholesale distribution of AcnEase
that becomes one of the focal point of marketing effort in
2017.
-The Company is
pursuing the number of venues to monetize its sexual Botanical
Therapeutics.
-The Company
identified and secured the product extension and products line
extension opportunities for AcnEase Skin Management System planned
to be introduced in 2017.
Outlook for
2017:
Herborium
remains very optimistic about growing its business, sales and
product awareness in the US and abroad.,
The Company continues
its efforts to increase market penetration in both retail and
wholesale sectors with the latest becoming a priority in
2017.
The Company also
continues to decrease costs and retire debt. While the
Company is still recognizing the expenses associated with
developing new markets and preparing the launch of new products
Herborium continues its growth, its search for partners and
creative financing opportunities to support this growth.
About
Herborium Group, Inc.
Herborium Group, Inc.
is a Botanical Therapeutics® company that develops, licenses and
markets proprietary, botanical based medicinal products to
consumers and healthcare professionals. The Company’s business
model focuses on emerging market opportunities spearheaded by the
growth of a new market sector located between high-cost,
high-risk, ethical pharmaceuticals and commoditized classic
nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA
Guidance 2004) to establish and maintain a differential
advantage. Herborium has secured a pipeline of botanical
ingredients based products in the areas of dermatological needs,
wellness and energy, prostate health, women’s health and selected
sexual disorders resulting from cardiovascular disease, use of
anti-depressants, diabetes, surgical procedures, and other issues.
Herborium Group sells its products in the United States, the United
Kingdom, and continental Europe through a network of distributors,
specialty retailers, and e-commerce. For more information, please
visit www.herborium.com,
www.acnease.com,
www.acnease.fr.www.acneasesp.com,
www.acnease.co.uk.
Safe Harbor Statement: This release
contains forward-looking statements with respect to the results of
operations and business of Herborium Group, Inc., which involves risks and
uncertainties. The Company's actual future results could
materially differ from those discussed. The Company
intends that such statements about the Company's future
expectations, including future revenues and earnings, and all other
forward looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of
1995.
Contact Information:
Herborium Group, Inc.
Email: InvestorsRelations@Herborium.com
or DrAgnes@Herborium.com
Herborium (PK) (USOTC:HBRM)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Herborium (PK) (USOTC:HBRM)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
